Kidney Disease After COVID-19
- Conditions
- COVID-19Chronic Kidney InjuryAcute Kidney Injury
- Registration Number
- NCT05328986
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Brief Summary
To understand the long-term epidemiology, develop effective risk-prediction and stratification tools, and understand the pathobiology of kidney disease in COVID-19 survivors.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 3000
- Adults, age ≥18 years
- Confirmed diagnosis of COVID-19
• No confirmed diagnosis of COVID-19
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method estimated Glomerular Filtration Rate (eGFR) yearly for 4 years after COVID exposure Kidneys filter blood by removing waste and extra water to make urine. The kidney's filtration rate, called the glomerular filtration rate (GFR), shows how well the kidneys are filtering. A normal GFR is 60 or higher.
- Secondary Outcome Measures
Name Time Method Urine Albumin-to-Creatinine Ratio (UACR) yearly for 4 years after COVID exposure Albuminuria is present when UACR is greater than 30 mg/g and is a marker for chronic kidney disease. Albuminuria is used to diagnose and monitor kidney disease.
Urine protein/creatinine ratio (UPCR) yearly for 4 years after COVID exposure Urine protein/creatinine ratio - Protein creatinine ratio in the urine quantifies the loss of the protein and helps in further evaluation of the kidney function. Normal ratio: \< 0.20
Trial Locations
- Locations (5)
Yale School of Medicine
🇺🇸New Haven, Connecticut, United States
Johns Hopkins University
🇺🇸Baltimore, Maryland, United States
University of Michigan
🇺🇸Ann Arbor, Michigan, United States
New Jersey Medical School - Rutgers University
🇺🇸Newark, New Jersey, United States
Icahn School of Medicine at Mount Sinai
🇺🇸New York, New York, United States